- Cellipont Bioservices and Secretome Therapeutics have announced a partnership to support the cGMP manufacturing of STM-01, a cell therapy designed to treat cardiovascular diseases.
- The collaboration will include technology transfer, analytical method transfer, and the creation of a Master Cell Bank for STM-01.
Cellipont Bioservices, a prominent Contract Development and Manufacturing Organization (CDMO), has formed a strategic partnership with Secretome Therapeutics, a biotechnology company focused on therapies derived from neonatal cardiac progenitor cells (nCPCs). This collaboration is aimed at advancing the cGMP manufacturing of Secretome’s lead asset, STM-01, a novel cellular therapy designed to treat severe cardiovascular diseases, including dilated cardiomyopathy (DCM) and heart failure with preserved ejection fraction (HFpEF).
Under the agreement, Cellipont Bioservices will manage the technology transfer, analytical method transfer, and provide cGMP manufacturing services for the STM-01 Master Cell Bank. STM-01, which is protected by a recently issued composition of matter patent, leverages the regenerative potential of nCPCs to address inflammation, fibrosis, and tissue repair in patients suffering from heart failure.
STM-01 is expected to enter Phase 1 clinical trials in the first quarter of 2025, with two multiple-ascending dose trials planned to assess its safety and efficacy. In addition to STM-01, Secretome Therapeutics is also developing STM-21, a secretome-based therapeutic aimed at treating chronic inflammatory conditions such as skin wounds and neurodegenerative diseases. STM-21 is currently in preclinical development.
“This partnership with Secretome Therapeutics represents an exciting opportunity for Cellipont to support the advancement of cutting-edge cell therapies,” said Darren Head, CEO of Cellipont Bioservices. “We are very excited to collaborate with a company so dedicated to developing innovative solutions that address significant unmet medical needs and improve patient outcomes.”
Vinny Jindal, President and CEO of Secretome Therapeutics, expressed confidence in the partnership, stating, “Cellipont’s world-class facility and deep expertise in cGMP manufacturing for cell and gene therapies make them an ideal manufacturing partner and align perfectly with our mission to deliver transformative therapies for cardiovascular diseases and beyond.”